DCGI clears SII, Bharat Biotech's COVID-19 vaccines: What emergency use authorisation means and why it is essential

-

Editor's note: This explainer is being republished in light of the DCGI's approval for restricted emergency use of the COVID-19 vaccines developed by Bharat Biotech and the Serum Institute of India.

The Drugs Controller General of India (DCGI) on Sunday approved the COVID-19 vaccines developed by Bharat Biotech, and Serum Institute of India (SII) for restricted emergency use.

In December 2020, as many as three pharmaceutical firms had applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for COVID-19 vaccines that they are developing.

HFW - DCGI Energency Use Authorisation- 3rd January 2021-2 by Natasha T. on Scribd

The Indian arm of US pharmaceutical giant Pfizer had on 4 December sought approval for its vaccine from the central drug regulator, after the firm secured such clearance in the UK and Bahrain. The Pune-based Serum Institute of India sought the nod for the Oxford COVID-19 vaccine, Covishield, on 6 December. Bharat Biotech has sought emergency approval for its indigeneously-developed vaccine Covaxin.

 

In this context, it comes important to understand what emergency use approval for a vaccine means.

What is emergency use approval?

Manufacturers of vaccines, medicines, diagnostic tests and medical devices have to obtain approval from regulatory authorities before these can be used on the general public.

These approvals depend on an assessment of the safety and effectiveness of these vaccines, medicines, etc., based on data from trials. Each phase of the trials also has to be approved by the regulators.

In India, drug regulations do not have provisions for emergency use approval and the process for receiving one is not clearly defined or consistent, an article in Hindustan Times notes. However, the unprecedented crisis in the form of the COVID-19 pandemic has led authorities to issue such approvals in recent months. The CDSCO has granted emergency or restricted emergency approvals to remdesivir and favipiravir for COVID-19 treatment in June and itolizumab in July.

However, the exact process by which such emergency use approvals are granted is not clear. An article in The Indian Express quotes Murali Neelakantan, lawyer and former global general counsel for Cipla and Glenmark Pharmaceuticals, as saying, "We still don't know the story behind these approvals — we haven't seen the clinical trial data published anywhere and we haven't seen the protocols that were followed for each drug."

The article quoted a senior government official as saying that any company seeking to launch a vaccine approved elsewhere will have to conduct local trials to show that it is safe and effective on the Indian population.

While there is no specific policy on emergency use approval in India, a look at such a policy in the United States gives us an idea of what it could entail. The US' Food and Drug Administration Commissioner can allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases. Such approval can also be granted in situations of chemical or biological warfare.

However, the emergency use approval can only be granted if the "known and potential benefits outweigh the known and potential risks" of the vaccine. Also, such an application can only be considered if sufficient efficacy data from phase 3 trials are known.

What next?

A PTI report quoted a source as saying, “DCGI has already started processing the applications. The subject expert committee (SEC) on COVID-19 at CDSCO will deliberate on the applications by Pfizer, Serum Institute of India and Bharat Biotech seeking emergency use authorisation for their COVID-19 vaccines on December 9.”

After evaluation, the SEC will give its recommendations to the DCGI on whether emergency use approval for the vaccine candidates should be granted or not, the source said.

At an all-party meeting on 4 December, Prime Minister Narendra Modi had expressed hope that a COVID-19 vaccine may be ready in a few weeks.

With inputs from PTI



from Firstpost India Latest News https://ift.tt/388JsAj
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

120 flights delayed, 30 trains running late; Delhi fog & cold wave continue to give shiver to travellers

-
Arrival and departure of 120 flights, both domestic and international, to Delhi airport were affected due to dense fog and cold wave conditions on Wednesday, according to Delhi Airport FIDS (Flight Information Display System). As per the Delhi Airport FIDS, a total of 53 flights, including 21 domestic arrivals, 16 domestic departures, 13 international departures and three international arrivals scheduled are cancelled and not operating due to fog and other operational reasons from and to Indira Gandhi International (IGI) Airport in the national capital on 17 January. #WATCH | Delhi: Several flight operations delayed at IGI airport due to low visibility amid fog. pic.twitter.com/hG1DUKllEt — ANI (@ANI) January 17, 2024 Visuals from the Delhi airport showed passengers waiting outside, checking update of their scheduled flights. There were also some people waiting for flight of their families, friends and loved ones to arrive, which got delayed due to fog. #WATCH | Delhi | Pas
Read more